164 related articles for article (PubMed ID: 17634951)
1. Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do.
Najar HM; Dutz JP
Eur J Immunol; 2007 Aug; 37(8):2242-56. PubMed ID: 17634951
[TBL] [Abstract][Full Text] [Related]
2. Topical resiquimod promotes priming of CTL to parenteral antigens.
Chang BA; Cross JL; Najar HM; Dutz JP
Vaccine; 2009 Sep; 27(42):5791-9. PubMed ID: 19660592
[TBL] [Abstract][Full Text] [Related]
3. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
Wingender G; Garbi N; Schumak B; Jüngerkes F; Endl E; von Bubnoff D; Steitz J; Striegler J; Moldenhauer G; Tüting T; Heit A; Huster KM; Takikawa O; Akira S; Busch DH; Wagner H; Hämmerling GJ; Knolle PA; Limmer A
Eur J Immunol; 2006 Jan; 36(1):12-20. PubMed ID: 16323249
[TBL] [Abstract][Full Text] [Related]
4. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells.
Maurer T; Heit A; Hochrein H; Ampenberger F; O'Keeffe M; Bauer S; Lipford GB; Vabulas RM; Wagner H
Eur J Immunol; 2002 Aug; 32(8):2356-64. PubMed ID: 12209649
[TBL] [Abstract][Full Text] [Related]
5. The synthetic TLR2 agonist BPPcysMPEG leads to efficient cross-priming against co-administered and linked antigens.
Prajeeth CK; Jirmo AC; Krishnaswamy JK; Ebensen T; Guzman CA; Weiss S; Constabel H; Schmidt RE; Behrens GM
Eur J Immunol; 2010 May; 40(5):1272-83. PubMed ID: 20213735
[TBL] [Abstract][Full Text] [Related]
6. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
7. Heat shock protein-antigen fusions lose their enhanced immunostimulatory capacity after endotoxin depletion.
Marincek BC; Kühnle MC; Srokowski C; Schild H; Hämmerling G; Momburg F
Mol Immunol; 2008 Nov; 46(1):181-91. PubMed ID: 18804283
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route.
Lombardi V; Van Overtvelt L; Horiot S; Moussu H; Chabre H; Louise A; Balazuc AM; Mascarell L; Moingeon P
Clin Exp Allergy; 2008 Nov; 38(11):1819-29. PubMed ID: 18644025
[TBL] [Abstract][Full Text] [Related]
9. Phosphatidylinositol mannosides are efficient mucosal adjuvants.
Parlane NA; Denis M; Severn WB; Skinner MA; Painter GF; La Flamme AC; Ainge GD; Larsen DS; Buddle BM
Immunol Invest; 2008; 37(2):129-42. PubMed ID: 18300038
[TBL] [Abstract][Full Text] [Related]
10. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
11. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine.
den Brok MH; Sutmuller RP; Nierkens S; Bennink EJ; Toonen LW; Figdor CG; Ruers TJ; Adema GJ
Cancer Res; 2006 Jul; 66(14):7285-92. PubMed ID: 16849578
[TBL] [Abstract][Full Text] [Related]
12. Blockade of TLR9 agonist-induced type I interferons promotes inflammatory cytokine IFN-gamma and IL-17 secretion by activated human PBMC.
Meyers JA; Mangini AJ; Nagai T; Roff CF; Sehy D; van Seventer GA; van Seventer JM
Cytokine; 2006 Sep; 35(5-6):235-46. PubMed ID: 17052915
[TBL] [Abstract][Full Text] [Related]
13. CpG-B ODNs potently induce low levels of IFN-alphabeta and induce IFN-alphabeta-dependent MHC-I cross-presentation in DCs as effectively as CpG-A and CpG-C ODNs.
Gray RC; Kuchtey J; Harding CV
J Leukoc Biol; 2007 Apr; 81(4):1075-85. PubMed ID: 17227820
[TBL] [Abstract][Full Text] [Related]
14. Human Flt-3-ligand-mobilized dendritic cells require additional activation to drive effective immune responses.
Diener KR; Moldenhauer LM; Lyons AB; Brown MP; Hayball JD
Exp Hematol; 2008 Jan; 36(1):51-60. PubMed ID: 17949888
[TBL] [Abstract][Full Text] [Related]
15. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb.
Murillo O; Dubrot J; Palazón A; Arina A; Azpilikueta A; Alfaro C; Solano S; Ochoa MC; Berasain C; Gabari I; Pérez-Gracia JL; Berraondo P; Hervás-Stubbs S; Melero I
Eur J Immunol; 2009 Sep; 39(9):2424-36. PubMed ID: 19662633
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG-oligodeoxynucleotides.
Inoue J; Aramaki Y
Vaccine; 2007 Jan; 25(6):1007-13. PubMed ID: 17049678
[TBL] [Abstract][Full Text] [Related]
17. TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines.
Tudor D; Dubuquoy C; Gaboriau V; Lefèvre F; Charley B; Riffault S
Vaccine; 2005 Jan; 23(10):1258-64. PubMed ID: 15652668
[TBL] [Abstract][Full Text] [Related]
18. Mediastinal lymph node CD8alpha- DC initiate antigen presentation following intranasal coadministration of alpha-GalCer.
Ko SY; Lee KA; Youn HJ; Kim YJ; Ko HJ; Heo TH; Kweon MN; Kang CY
Eur J Immunol; 2007 Aug; 37(8):2127-37. PubMed ID: 17615581
[TBL] [Abstract][Full Text] [Related]
19. Synthetic nanoparticle vaccines produced by layer-by-layer assembly of artificial biofilms induce potent protective T-cell and antibody responses in vivo.
Powell TJ; Palath N; DeRome ME; Tang J; Jacobs A; Boyd JG
Vaccine; 2011 Jan; 29(3):558-69. PubMed ID: 20951665
[TBL] [Abstract][Full Text] [Related]
20. Antigen delivery for cross priming via the emulsion vaccine adjuvants.
Shen SS; Yang YW
Vaccine; 2012 Feb; 30(9):1560-71. PubMed ID: 22230588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
